Outlook Therapeutics
OTLK
73 hedge funds and large institutions have $45.3M invested in Outlook Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
39% more capital invested
Capital invested by funds: $32.6M → $45.3M (+$12.7M)
4% more funds holding
Funds holding: 70 → 73 (+3)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
0.03% more ownership
Funds ownership: 0.53% → 0.57% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Vista Finance
Clayton,
Missouri
|
+$1.54M |
| 2 |
BlackRock
New York
|
+$1.19M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.11M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$516K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$834K |
| 2 |
Renaissance Technologies
New York
|
-$679K |
| 3 |
Two Sigma Advisers
New York
|
-$546K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$517K |
| 5 |
IA
IndexIQ Advisors
New York
|
-$255K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
76
STRS Ohio
Columbus,
Ohio
| – | -$36K | -1,350 | Closed |
|
77
SG Americas Securities
New York
| – | -$34K | -1,262 | Closed |
|
|
OC
78
Oppenheimer & Co
New York
| – | -$30K | -1,105 | Closed |
|
|
HLOC
79
H.L. Ormond & Company
Greenville,
North Carolina
| – | -$13K | -500 | Closed |
|
|
ACM
80
Aquatic Capital Management
Chicago,
Illinois
| – | -$14.1K | -450 | -99% |
|
|
CFGS
81
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2.15K | -69 | Closed |
|
|
SBL
82
Sargent Bickham Lagudis
Boulder,
Colorado
| – | -$1K | -50 | Closed |
|
OTLK Hedge Fund Activity: Q1 2022 in Review
73 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2022, worth a combined $45.3M — up 39% from $32.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OTLK positions and 9 closed out — a net gain of 5 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was Vista Finance, opening a new position worth an estimated $1.54M. The largest seller was Two Sigma Investments, cutting an estimated $834K.
- 73 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2022, up from 70 in Q4 2021.
- Funds reported $45.3M of Outlook Therapeutics stock for Q1 2022, up 39% quarter-over-quarter.
- 14 funds opened new Outlook Therapeutics positions in Q1 2022 and 9 closed out, a net change of +5 holders.
- The largest Outlook Therapeutics buyer in Q1 2022 was Vista Finance, an estimated $1.54M added.
- The largest Outlook Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $834K sold.
Based on aggregated 13F filings for Q1 2022.